Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital

Bluejay Diagnostics, Inc.

Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.
SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.
Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.
Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.